Bibliographic Details
| Title: |
Longitudinal Tumor Size and Survival Modeling for Exposure-Response Analysis of Drugs with Frequent Dose Reductions: Dose Justification of Abemaciclib in Patients with Metastatic Breast Cancer. |
| Authors: |
Chigutsa E; Eli Lilly and Company, Indianapolis, Indiana, USA., Chapman SC; Eli Lilly and Company, Indianapolis, Indiana, USA., Turner PK; Eli Lilly and Company, Indianapolis, Indiana, USA. |
| Source: |
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2026 Apr; Vol. 119 (4), pp. 1070-1079. Date of Electronic Publication: 2026 Jan 27. |
| Publication Type: |
Journal Article |
| Journal Info: |
Publisher: Wiley Country of Publication: United States NLM ID: 0372741 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-6535 (Electronic) Linking ISSN: 00099236 NLM ISO Abbreviation: Clin Pharmacol Ther Subsets: MEDLINE |
| Database: |
MEDLINE Ultimate |
